NOVARTIS AG-SPONSORED ADR (NVS:NYSE)
$147.38 -0.59 (-0.3987%)
Analysed NOVARTIS AG-SPONSORED ADR (NVS:NYSE) News Sources
Roche Highlights Gazyva Progress, Reports Data on Enspryng, MS Drug
22-04-2026
yahoo.com
Sjogren's Syndrome Market Analysis Report 2025-2035 Featuring Novartis, Otsuka Pharmaceutical, Nicox, and Bristol Myers Squibb
22-04-2026
yahoo.com
Neuroblastoma Treatment Market Analysis Report 2025-2035 - Regional Players and Local Manufacturers are Expected to Play an Important Role in Future Growth
22-04-2026
yahoo.com
This Biotech Stock Is Up 460% Over the Past Year. Why Analysts See It Rising Higher.
21-04-2026
yahoo.com
BIIB Inks Deal to Acquire Rights to Felzartamab in China, Stock Up
21-04-2026
yahoo.com
AstraZeneca's Ultomiris Meets Goal in Rare Kidney Disease Study
21-04-2026
yahoo.com
Eli Lilly Snags $7 Billion Cancer Deal To Rival Gilead, J&J, Others
20-04-2026
yahoo.com
Assessing Novartis (SWX:NOVN) Valuation After Recent Share Price Moves And Long Term Returns
19-04-2026
yahoo.com
Better Pharma Dividend Stock: Novartis vs. Merck
17-04-2026
fool.com
3 Best Vanguard Dividend ETFs for Reliable Passive Income in 2026
17-04-2026
yahoo.com
What is the current price of NOVARTIS AG-SPONSORED ADR (NVS:NYSE)?
The current price of NOVARTIS AG-SPONSORED ADR (NVS:NYSE) is $147.38.
NOVARTIS AG-SPONSORED ADR (NVS:NYSE) absolute price change since previous trading day?
The absolute price change of NOVARTIS AG-SPONSORED ADR (NVS:NYSE) since the previous trading day is $-0.59.
NOVARTIS AG-SPONSORED ADR (NVS:NYSE) percentage price change since previous trading day?
The percentage price change of NOVARTIS AG-SPONSORED ADR (NVS:NYSE) since the previous trading day is -0.3987%.
What is the most recent average sentiment score for NOVARTIS AG-SPONSORED ADR (NVS:NYSE)?
The most recent average sentiment score for NOVARTIS AG-SPONSORED ADR (NVS:NYSE) is 77 out of 100.
What is the most recent average sentiment for NOVARTIS AG-SPONSORED ADR (NVS:NYSE)?
The most recent sentiment for NOVARTIS AG-SPONSORED ADR (NVS:NYSE) is .
SEC-8K** Filing Available For NOVARTIS AG-SPONSORED ADR (NVS:NYSE)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.